Stockreport

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

ATAI Life Sciences N.V. - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe and well-tolera [Read more]